About MagicMed
MagicMed Industries Inc. is a biotechnology company founded in 2020. The company is focused on creating a library of novel derivative molecules based on classic psychedelics such as psilocybin, N,N-dimethyltryptamine (DMT), mescaline, ibogaine, MDMA and LSD. MagicMed’s molecular derivatives library, the Psybrary™, is intended to be an essential building block from which industry partners can develop new patented products.
Mission
MagicMed is focused on the discovery and early development of novel drug candidates, structurally related to the classic psychedelics but with vastly improved pharmaceutical characteristics and commercial potential.
The Need
There has been a resurgence of interest in psychedelics as researchers look to create alternative treatment solutions for a growing patient base.
Early clinical results, increased corporate and media support and a regulatory thaw of these Schedule I compounds have created the perfect framework for the industry to benefit from what psychedelics have to offer.
In the last few years, classic psychedelics have shown the potential to provide an improved, alternative treatment solution to a vast array of mental health indications – ranging from treatment-resistant depression and anxiety to PTSD.
The Team
Dr. Joseph Tucker
CEO
Dr. Joseph Tucker is a seasoned executive who has built several publicly traded biotechnology companies. Dr. Tucker was a founder and Chief Executive Officer of Stem Cell Therapeutics, which he took public on the TSX (TSX: SSS). Trillium Therapeutics (NASDAQ: TRIL, TSX: TRIL) acquired Stem Cell Therapeutics in 2013. Dr. Tucker has also held the position of Co-Founder and Chief Executive Officer of Epimeron Inc., a University of Calgary start-up acquired in the creation of Willow Biosciences Inc. (TSX: WLLW). At Willow, Dr. Tucker served as Executive Chairman and Chief Operating Officer. Prior to founding companies, Dr. Tucker was a healthcare analyst with two investment banks and has also worked in technology commercialization for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.
Dr. Jillian Hagel
CTO
Dr. Jillian Hagel is the Chief Technology Officer for MagicMed Industries Inc. Jill leads the science team in delivering milestones and science program coordination. Dr. Hagel has over 19 years’ experience in plant biochemistry and natural products biosynthesis. Before co-founding MagicMed Industries, Dr. Hagel held the position of Vice President, Applied Science and co-founder of Willow Biosciences Inc. (TSX: WLLW). Dr. Hagel was COO of Epimeron Inc. before the acquisition of Epimeron by Willow. Dr. Hagel has coauthored over 35 peer-reviewed publications and is the co-inventor on many patent applications. Dr. Jillian Hagel received her Ph.D. in natural products biochemistry in 2010 from the University of Calgary.
Dr. Peter Facchini
CSO
Dr. Peter Facchini is the Chief Scientific Officer of MagicMed Industries, Inc. Dr. Facchini has been a Professor of Plant Biochemistry in the Department of Biological Sciences at the University of Calgary for 25 years. Dr. Facchini held the Canada Research Chair in Plant Metabolic Processes Biotechnology and is currently a Parex Resources Innovation Fellow in the Faculty of Science. Dr. Facchini co-founded and was Chief Scientific Officer of Willow Biosciences Inc. and Epimeron Inc. Dr. Facchini has published over 160 scientific papers and co-invented over 30 patents. Dr. Facchini is an international leader in the biochemistry and biotechnology of natural product metabolism.